Talphera (TLPH) Competitors $0.59 -0.03 (-5.48%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.57 -0.02 (-2.73%) As of 03/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLPH vs. ICCC, LTRN, RNTX, DTIL, KALA, BRNS, XLO, ATRA, SCYX, and DYAIShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include ImmuCell (ICCC), Lantern Pharma (LTRN), Rein Therapeutics (RNTX), Precision BioSciences (DTIL), KALA BIO (KALA), Barinthus Biotherapeutics (BRNS), Xilio Therapeutics (XLO), Atara Biotherapeutics (ATRA), SCYNEXIS (SCYX), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Talphera vs. ImmuCell Lantern Pharma Rein Therapeutics Precision BioSciences KALA BIO Barinthus Biotherapeutics Xilio Therapeutics Atara Biotherapeutics SCYNEXIS Dyadic International Talphera (NASDAQ:TLPH) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Which has preferable valuation and earnings, TLPH or ICCC? ImmuCell has higher revenue and earnings than Talphera. ImmuCell is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$281K35.51-$18.40M-$0.69-0.85ImmuCell$26.49M1.69-$5.78M-$0.29-17.28 Does the media refer more to TLPH or ICCC? In the previous week, Talphera had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Talphera and 3 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.21 beat Talphera's score of 0.22 indicating that ImmuCell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmuCell 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TLPH or ICCC? Talphera presently has a consensus price target of $4.33, suggesting a potential upside of 639.48%. Given Talphera's stronger consensus rating and higher probable upside, analysts plainly believe Talphera is more favorable than ImmuCell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50ImmuCell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, TLPH or ICCC? Talphera has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, ImmuCell has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Do insiders & institutionals believe in TLPH or ICCC? 37.7% of Talphera shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 3.2% of Talphera shares are owned by insiders. Comparatively, 6.6% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor TLPH or ICCC? ImmuCell received 112 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 73.33% of users gave ImmuCell an outperform vote. CompanyUnderperformOutperformTalpheraOutperform Votes9100.00% Underperform VotesNo VotesImmuCellOutperform Votes12173.33% Underperform Votes4426.67% Is TLPH or ICCC more profitable? Talphera has a net margin of 0.00% compared to ImmuCell's net margin of -15.99%. ImmuCell's return on equity of -15.32% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -118.46% -65.82% ImmuCell -15.99%-15.32%-8.81% SummaryTalphera beats ImmuCell on 10 of the 19 factors compared between the two stocks. Remove Ads Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.98M$6.90B$5.63B$7.84BDividend YieldN/A2.76%5.33%4.01%P/E Ratio-0.857.2623.5518.73Price / Sales35.51218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book0.716.386.894.23Net Income-$18.40M$142.34M$3.20B$247.47M7 Day Performance-7.67%-5.15%-3.06%-2.29%1 Month Performance4.74%-7.55%1.51%-5.81%1 Year Performance-43.11%-11.06%9.37%-0.96% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera2.1073 of 5 stars$0.59-5.5%$4.33+639.5%-43.1%$9.98M$281,000.00-0.8519Upcoming EarningsShort Interest ↑News CoverageICCCImmuCell0.7864 of 5 stars$4.78-2.6%N/A-5.5%$42.61M$26.49M-9.5670Short Interest ↓LTRNLantern Pharma0.7387 of 5 stars$3.90+2.1%N/A-59.7%$42.06MN/A-2.1920Earnings ReportNews CoverageRNTXRein TherapeuticsN/A$1.93+1.0%N/AN/A$41.82MN/A-0.629Gap UpDTILPrecision BioSciences4.2999 of 5 stars$5.64+3.5%$37.67+567.8%-65.3%$41.81M$75.10M94.02200Earnings ReportAnalyst ForecastShort Interest ↓Gap UpKALAKALA BIO3.9566 of 5 stars$6.86-0.9%$15.00+118.7%-24.1%$41.78M$3.89M-0.5530Upcoming EarningsBRNSBarinthus Biotherapeutics2.2286 of 5 stars$1.03+4.0%$5.17+401.6%-55.9%$41.44M$14.97M-0.69107Short Interest ↑Gap DownXLOXilio Therapeutics3.3213 of 5 stars$0.79-0.5%$4.00+409.1%-30.9%$40.68M$6.34M-0.4670Short Interest ↓ATRAAtara Biotherapeutics4.126 of 5 stars$6.94+4.7%$17.75+155.8%-62.4%$40.66M$128.94M-0.27330SCYXSCYNEXIS1.0815 of 5 stars$1.04flatN/A-32.0%$40.54M$3.75M-1.4160DYAIDyadic International2.2741 of 5 stars$1.37-2.8%$6.00+338.0%-18.0%$40.54M$3.36M-5.967Earnings ReportNews CoverageGap Down Remove Ads Related Companies and Tools Related Companies ImmuCell Alternatives Lantern Pharma Alternatives Rein Therapeutics Alternatives Precision BioSciences Alternatives KALA BIO Alternatives Barinthus Biotherapeutics Alternatives Xilio Therapeutics Alternatives Atara Biotherapeutics Alternatives SCYNEXIS Alternatives Dyadic International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLPH) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLPH Stock Free TLPH Stock Alerts